| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andrea Giustina, Gherardo Mazziotti, Valter Torri, Maurizio Spinello, Irene Floriani, Shlomo Melme. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PloS one. vol 7. issue 5. 2012-09-10. PMID:22574156. |
the long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (gh) levels in patients with acromegaly and may also induce pituitary tumor shrinkage. |
2012-09-10 |
2023-08-12 |
Not clear |
| Christopher R Palmeiro, Rishi Anand, Inderpreet Kaur Dardi, Nivas Balasubramaniyam, Monica D Schwarcz, Irene A Weis. Growth hormone and the cardiovascular system. Cardiology in review. vol 20. issue 4. 2012-08-28. PMID:22314142. |
acromegaly, a state of endogenous gh excess, results in myocardial hypertrophy and decreased cardiac performance with increased cardiovascular mortality. |
2012-08-28 |
2023-08-12 |
human |
| L Sze, R L Bernays, C Zwimpfer, P Wiesli, M Brändle, C Schmi. Excessively high soluble Klotho in patients with acromegaly. Journal of internal medicine. vol 272. issue 1. 2012-08-24. PMID:22452701. |
the aim of our study was to examine the relationship between excess growth hormone (gh) and serum levels of klotho in patients with acromegaly, a disease usually caused by a pituitary adenoma, which is associated with high phosphate levels and reduced life expectancy. |
2012-08-24 |
2023-08-12 |
mouse |
| G Minniti, C Scaringi, D Amelio, R Maurizi Enric. Stereotactic Irradiation of GH-Secreting Pituitary Adenomas. International journal of endocrinology. vol 2012. 2012-08-23. PMID:22518123. |
radiotherapy (rt) is often employed in patients with acromegaly refractory to medical and/or surgical interventions in order to prevent tumour regrowth and normalize elevated gh and igf-i levels. |
2012-08-23 |
2023-08-12 |
Not clear |
| Gloria Lugo, Lara Pena, Fernando Cordid. Clinical manifestations and diagnosis of acromegaly. International journal of endocrinology. vol 2012. 2012-08-23. PMID:22518126. |
acromegaly and gigantism are due to excess gh production, usually as a result of a pituitary adenoma. |
2012-08-23 |
2023-08-12 |
Not clear |
| Gloria Lugo, Lara Pena, Fernando Cordid. Clinical manifestations and diagnosis of acromegaly. International journal of endocrinology. vol 2012. 2012-08-23. PMID:22518126. |
it has been suggested that the rate of mortality in patients with acromegaly is correlated with the degree of control of gh. |
2012-08-23 |
2023-08-12 |
Not clear |
| E Diaz-Rodriguez, M García-Lavandeira, S Perez-Romero, A Senra, C Cañibano, I Palmero, M G Borrello, C Dieguez, C V Alvare. Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells. Oncogene. vol 31. issue 23. 2012-08-21. PMID:22020338. |
thus pit-1, a differentiation factor, activates the oncogene-induced apoptosis (oia) pathway as oncogenes exerting a tight control in somatotrophs to prevent the disease due to excess of gh (insulin-resistance, metabolic disease, acromegaly). |
2012-08-21 |
2023-08-12 |
Not clear |
| Marek Pawlikowski, Joanna Kuta, Julitta Fuss-Chmielewska, Katarzyna Winczy. 'Silent' somatotropinoma. Endokrynologia Polska. vol 63. issue 2. 2012-08-16. PMID:22538745. |
'silent' somatotropinomas are defined as gh-immunopositive pituitary adenomas without clinical symptoms of acromegaly and gh elevation in peripheral blood. |
2012-08-16 |
2023-08-12 |
Not clear |
| Hitoshi Nishizawa, Anastasia-Evi Handayaningsih, Genzo Iguchi, Yoshitake Cho, Michiko Takahashi, Masaaki Yamamoto, Kentaro Suda, Kohei Kasahara, Fumihiko Hakuno, Keitaro Yamanouchi, Masugi Nishihara, Susumu Seino, Shin-Ichiro Takahashi, Yutaka Takahash. Enhanced oxidative stress in GH-transgenic rat and acromegaly in humans. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 22. issue 2. 2012-08-08. PMID:22370764. |
acromegaly is a pathological condition associated with excess growth hormone (gh) and insulin-like growth factor-i (igf-i) and a high prevalence of diabetes, hypertension, atherosclerosis, and heart failure; resulting in premature death. |
2012-08-08 |
2023-08-12 |
rat |
| Elena Valassi, Danielle J Brick, Jessica C Johnson, Beverly M K Biller, Anne Klibanski, Karen K Mille. Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 18. issue 2. 2012-08-08. PMID:22440981. |
to compare the response in quality of life (qol) to growth hormone (gh) replacement in women with gh deficiency (ghd) and a history of acromegaly with that in women with ghd of other causes. |
2012-08-08 |
2023-08-12 |
Not clear |
| María J Garrido, Josep-María Cendrós, Joaquim Ramis, Concepción Peraire, Rosendo Obach, Iñaki F Trocóni. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1. Journal of clinical pharmacology. vol 52. issue 4. 2012-07-27. PMID:21551318. |
acromegaly arises from excessive levels of growth hormone (gh), many of whose effects are mediated by stimulation of secretion of insulin-like growth factor 1 (igf-1). |
2012-07-27 |
2023-08-12 |
Not clear |
| María J Garrido, Josep-María Cendrós, Joaquim Ramis, Concepción Peraire, Rosendo Obach, Iñaki F Trocóni. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1. Journal of clinical pharmacology. vol 52. issue 4. 2012-07-27. PMID:21551318. |
the objective of the study was to develop a population pharmacodynamic model describing the relationship between serum concentrations of lanreotide (c(p)) and its gh and igf-1 effects in patients with acromegaly receiving lanreotide autogel (la) at doses of 60, 90, or 120 mg by deep subcutaneous route every 28 days. |
2012-07-27 |
2023-08-12 |
Not clear |
| Fatih M Erdur, Türker Kilic, Selcuk Peker, Ozlem Celik, Pinar Kadiogl. Gammaknife radiosurgery in patients with acromegaly. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 18. issue 12. 2012-07-19. PMID:22001240. |
we concluded that gkr is an effective adjuvant treatment to control tumour growth, lower gh and igf-1 levels, and to increase remission rates in patients with acromegaly who were refractory to surgical and medical treatment. |
2012-07-19 |
2023-08-12 |
Not clear |
| Annamaria Cola. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. vol 15. issue 1. 2012-07-16. PMID:21713528. |
in acromegaly, growth hormone (gh) and insulin-like growth factor-1 (igf-1) excess results in a specific cardiomyopathy characterized by concentric cardiac hypertrophy primarily associated with diastolic dysfunction that can lead to impaired systolic function and eventually heart failure. |
2012-07-16 |
2023-08-12 |
Not clear |
| Vicky Cheng, Charles Faiman, Laurence Kennedy, Fadi Khoury, Betul Hatipoglu, Robert Weil, Amir Hamrahia. Pregnancy and acromegaly: a review. Pituitary. vol 15. issue 1. 2012-07-16. PMID:21789529. |
the diagnosis of acromegaly during pregnancy is made difficult due to the physiologic changes in pituitary gh secretion and igf-1 production resulting from placental gh secretion and the inability of commercial assays to discriminate between pituitary and placental gh. |
2012-07-16 |
2023-08-12 |
Not clear |
| Emilie Morin, France Berthelet, John Weisnagel, Martin Bidlingmaier, Omar Serr. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary. vol 15. issue 1. 2012-07-16. PMID:20407837. |
it has been suggested that treatment with adequate dose titration of pegvisomant, a gh antagonist, up to a maximum of 40 mg daily, can achieve igf-1 normalisation in virtually all patients with acromegaly. |
2012-07-16 |
2023-08-12 |
Not clear |
| A Hannemann, H Wallaschofski, R Rettig, H Völzke, S Samietz, M Nauck, M Bidlingmaier, N Friedric. Association of IGF-I and the IGF-I/IGFBP-3 ratio with plasma aldosterone levels in the general population. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 44. issue 3. 2012-07-12. PMID:22328165. |
several studies in patients with acromegaly or growth hormone (gh) deficiency suggest a stimulatory effect of the growth hormone (gh)/insulin-like growth factor i (igf-i) axis on the renin-angiotensin-aldosterone system (raas). |
2012-07-12 |
2023-08-12 |
human |
| Xian-Ling Wang, Jing-Tao Dou, Zhao-Hui Lü, Wen-Wen Zhong, Jian-Ming Ba, Du Jin, Ju-Ming Lu, Chang-Yu Pan, Yi-Ming M. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma. Chinese medical journal. vol 124. issue 22. 2012-07-12. PMID:22340248. |
the typical presence of pituitary growth hormone (gh) adenoma is gigantism and/or acromegaly. |
2012-07-12 |
2023-08-12 |
Not clear |
| Xian-Ling Wang, Jing-Tao Dou, Zhao-Hui Lü, Wen-Wen Zhong, Jian-Ming Ba, Du Jin, Ju-Ming Lu, Chang-Yu Pan, Yi-Ming M. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma. Chinese medical journal. vol 124. issue 22. 2012-07-12. PMID:22340248. |
we investigated the clinical characteristics of patients with spontaneous partial remission of acromegaly or gigantism due to subclinical apoplexy of gh adenoma. |
2012-07-12 |
2023-08-12 |
Not clear |
| M Filopanti, C Giavoli, S Grottoli, A Bianchi, L De Marinis, E Ghigo, A Spad. The exon 3-deleted growth hormone receptor: molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions. Journal of endocrinological investigation. vol 34. issue 11. 2012-07-10. PMID:22322534. |
similar studies, performed in patients with acromegaly, assumed an influence of the d3- ghr variant in the relationship between gh and igf-i levels. |
2012-07-10 |
2023-08-12 |
human |